PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells

British Journal of Cancer

Volumn 109, Issue 7, 2013, Pages 1795-1804

  Chien, W ^a   Lee, K L ^a   Ding, L W ^a   Wuensche, P ^a   Kato, H ^a   Doan, N B ^b   Poellinger, L ^a   Said, J W ^b   Koeffler, H P ^a,c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

hypoxia; pancreatic cancer; PIAS4

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN INHIBITOR OF ACTIVATED STAT 4; SMALL INTERFERING RNA; STAT3 PROTEIN; SUMO 1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL HYPOXIA; CELL INVASION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; EXON; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; OLIGOMERIZATION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SUMOYLATION;

ADENOCARCINOMA; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; PANCREATIC NEOPLASMS; PROTEIN INHIBITORS OF ACTIVATED STAT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUMOYLATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84885171697     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.531     Document Type: Article

References (42)

1. Adachi Y, Yamamoto H, Ohashi H, Endo T, Carbone DP, Imai K, Shinomura Y (2010) A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers. World J Gastroenterol 16: 5779-5789.
2. Albor A, Kulesz-Martin M (2007) Novel initiation genes in squamous cell carcinomagenesis: a role for substrate-specific ubiquitylation in the control of cell survival. Mol Carcin 46: 585-590.
3. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Group AOCS, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD (2011) IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 17: 2538-2548.
4. Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P (2008) The histone demethylases JMJD1A and JMJD2B Are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 283: 36542-36552.
5. Bischof O, Schwamborn K, Martin N, Werner A, Sustmann C, Grosschedl R, Dejean A (2006) The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell 22: 783-794.
6. Buchholz M, Braun M, Heidenblut A, Kestler HA, Kloppel G, Schmiegel W, Hahn SA, Luttges J, Gress TM (2005) Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24: 6626-6636.
7. Cai QL, Robertson ES (2010) Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. PLoS One 5(9): e12636.
8. Cai QL, Verma SC, Kumar P, Ma M, Robertson ES (2010) Hypoxia inactivates the VHL tumour suppressor through PIASy-mediated SUMO modification. PLoS One 5(3): e9720.
9. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolo M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F (2010) Randomized Phase III Trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 Study. J Clin Oncol 28: 1645-1651.
10. Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N (2011) STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71: 5020-5029.
11. Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F, Ruszniewski P, Bedossa P (2008) Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumour aggressiveness in pancreatic endocrine tumours. Clin Cancer Res 14: 6634-6639.
12. Dadke S, Cotteret S, Yip S-C, Jaffer ZM, Haj F, Ivanov A, Rauscher F, Shuai K, Ng T, Neel BG, Chernoff J (2007) Regulation of protein tyrosine phosphatase 1B by sumoylation. Nat Cell Biol 9: 80-85.
13. Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-713.
14. Depaux A, Regnier-Ricard F, Germani A, Varin-Blank N (2007) A crosstalk between hSiah2 and Pias E3-ligases modulates Pias-dependent activation. Oncogene 26: 6665-6676.
15. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE (2005) HIF-1[alpha], STAT3, CBP//p300 and Ref-1//APE are components of a transcriptional complex that regulates Src-dependent hypoxiainduced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24: 3110-3120.
16. Gross M, Yang R, Top I, Gasper C, Shuai K (2004) PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene 23: 3059-3066.
17. Guo X, Shi M, Sun L, Wang Y, Gui Y, Cai Z, Duan X (2011) The expression of histone demethylase JMJD1A in renal cell carcinoma. Neoplasma 58: 153-157.
18. Ihara M, Yamamoto H, Kikuchi A (2005) SUMO-1 modification of PIASy, an E3 ligase, is necessary for PIASy-dependent activation of Tcf-4. Mol Cell Biol 25: 3506-3518.
19. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD, Pause A (1999) Identification of the von Hippel-Lindau tumour-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96: 12436-12441.
20. Jackson PK (2001) A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev 15: 3053-3058.
21. Kaelin Jr WG (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
22. Kang X, Li J, Zou Y, Yi J, Zhang H, Cao M, Yeh ETH, Cheng J (2010) PIASy stimulates HIF1[alpha] SUMOylation and negatively regulates HIF1[alpha] activity in response to hypoxia. Oncogene 29: 5568-5578.
23. Karamouzis MV, Konstantinopoulos PA, Badra FA, Papavassiliou AG (2008) SUMO and estrogen receptors in breast cancer. Breast Cancer Res Treat 107: 195-210.
24. Kataoka TR, Ioka T, Tsukamoto Y, Matsumura M, Ishiguro S, Nishizawa Y (2007) Nuclear expression of STAT5 in intraductal papillary mucinous neoplasms of the pancreas. Int J Surg Pathol 15: 277-281.
25. Koenig A, Mueller C, Hasel C, Adler G, Menke A (2006) Collagen Type I Induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res 66: 4662-4671.
26. Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ (2010) Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1{alpha} enhances hypoxic gene expression and tumour growth. Mol Cell Biol 30: 344-353.
27. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, Stoeltzing O (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1a autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13: 6459-6468.
28. Mabb AM, Wuerzberger-Davis SM, Miyamoto S (2006) PIASy mediates NEMO sumoylation and NF-[kappa]B activation in response to genotoxic stress. Nat Cell Biol 8: 986-993.
29. Moser C, Ruemmele P, Gehmert S, Schenk H, Kreutzz MP, Mycielska ME, Hackl C, Kroemer A, Schnitzbauer AA, Stoeltzing O, Schlitt HJ, Geissler EK, Lang SA (2012) STAT5b as molecular target in pancreatic cancer-inhibition of tumor growth, angiogenesis and metastases. Neoplasia 14: 11.
30. McCarthy N (2009) Pancreatic cancer on your marks. Nat Rev Cancer 9: 846.
31. Natoni F, Diolordi L, Santoni C, Montani MSG (2005) Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta-Mol Cell Res 1745: 318-329.
32. Nelson V, Davis GE, Maxwell SA (2001) A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis. Apoptosis 6: 221-234.
33. Ohmine K, Ota J, Ueda M, Ueno S, Yoshida K, Yamashita Y, Kirito K, Imagawa S, Nakamura Y, Saito K, Akutsu M, Mitani K, Kano Y, Komatsu N, Ozawa K, Mano H (2001) Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene 20: 8249-8257.
34. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R (2001) PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 15: 3088-3103.
35. Sun Y, Perera J, Rubin BP, Huang JT (2011) SYT-SSX1 (synovial sarcoma translocated) regulates PIASy ligase activity to cause overexpression of NCOA3 protein. J Biol Chem 286: 18623-18632.
36. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber H-P, Ferrara N, Johnson RS (2004) Loss of HIF-1a in endothelial cells disrupts a hypoxiadriven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6: 485-495.
37. Uemura M, Yamamoto H, Takemasa I, Mimori K, Hemmi H, Mizushima T, Ikeda M, Sekimoto M, Matsuura N, Doki Y, Mori M (2010) Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells. Clin Cancer Res 16: 4636-4646.
38. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Bjorling L, Ponten F (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotech 28: 1248-1250.
39. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. The Lancet 378: 607-620.
40. Wilkinson KA, Henley JM (2010) Mechanisms, regulation and consequences of protein sumoylation. Biochem J 428: 133-145.
41. Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410.
42. Zhong ZWZ, Darnell Jr. JE (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 4.